
Integrated exposure therapy reduced PTSD symptoms faster in young people with substance use
AI-summarized from the linked source. Educational brief, not medical advice.
Brief summary
In a randomized trial of 55 participants age 12 to 25 with co-occurring post-traumatic stress and substance use disorders, integrated exposure-based COPE-A produced greater and faster improvement in PTSD outcomes than person-centered supportive therapy.
What NurseJet pulled from the source
At four months, COPE-A produced a 9.82-point greater reduction in PTSD symptom severity and lower odds of meeting PTSD diagnostic criteria than the comparison therapy; improvements were maintained through 12 months. Both groups reduced substance use and disorder severity over time, with no significant between-group difference. Participants reported greater satisfaction with COPE-A, and no study-related adverse events were reported.
Why this matters for nurses
Mental-health nurses often care for young people whose trauma symptoms and substance use interact, complicating engagement and treatment planning. The trial supports coordinated treatment rather than requiring PTSD work to wait for substance-use remission, while leaving exposure therapy to appropriately trained clinicians.
Bedside takeaway
Integrated therapy accelerated PTSD improvement, while substance-use outcomes were similar and treatment still requires trained clinical oversight.
How This Applies in Practice
Use this when: Caring for an adolescent or young adult receiving clinician-directed treatment for co-occurring PTSD and substance use disorder.
On your shift
- Assess trauma symptoms, substance use, acute safety, and barriers to engagement as related but distinct parts of the care plan.
- Reinforce the therapist's coping and attendance plan and document symptom, substance-use, or safety changes between sessions.
- Communicate worsening distress, intoxication or withdrawal concerns, self-harm risk, or disengagement to the responsible mental-health team.
Explain this for my unit
Key takeaways
- The trial randomized 55 adolescents and young adults age 12 to 25 to COPE-A or person-centered supportive therapy.
- COPE-A produced a greater reduction in PTSD symptoms by the four-month primary endpoint.
- Substance-use outcomes improved over time in both groups without a significant between-group difference.
- The small single-region trial reported no study-related adverse events but cannot establish safety or effectiveness across all youth settings.
Practice implications
- Assess and document trauma symptoms, substance use, acute risk, engagement barriers, and treatment goals without framing one condition as a reason to ignore the other. Support attendance and coping plans, monitor response and safety, and communicate changes to the clinician delivering the integrated therapy.
Limitations & cautions
- The trial enrolled 55 participants in Sydney, most of whom were female, and compared two active psychotherapies. The small sample limits subgroup and uncommon-harm assessment, substance-use outcomes did not differ between groups, and results may not generalize to other ages, settings, treatment models, or levels of acuity.
- AI-summarized from the linked source. Review the original article before applying to practice.
Citations
Exact source links
Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.
European journal of psychotraumatology (PubMed)
European journal of psychotraumatology (PubMed). Integrated exposure-based therapy for co-occurring post-traumatic stress and substance use among young people: a randomized controlled trial.
https://pubmed.ncbi.nlm.nih.gov/42478200/
Professional education only


